Immunotherapy based on immune checkpoint inhibitor (ICI) has become the main treatment
strategy for advanced non-small cell lung cancer (NSCLC). By releasing immune checkpoint …

Immune checkpoint inhibitors have become an important alternative for advanced non-small
cell lung cancer (NSCLC) patients to surgery, chemotherapy, radiotherapy and targeted …

With the development of precise medicine, targeted therapy has greatly improved the
survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with …

Objectives Immune checkpoint inhibitors (ICI) monotherapy was standard of care in second-
line treatment of patients with advance non-small cell lung cancer (NSCLC). This study aims …

Abstract Introduction Immune checkpoint inhibitors (ICIs) have demonstrated long survival
for the treatment of advanced non-small cell lung cancer (NSCLC). However, the effect and …

Background Immunotherapy, monotherapy, and immunotherapy plus platinum-based
chemotherapy are the standard treatments for advanced non-small cell lung cancer …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Lung cancer is the most deadly disease in the world. The common treatment options include
surgery, chemotherapy and radiotherapy, and targeted therapy can also be used selectively …

Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer
(NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival …

Introduction: The recent emergence of immune checkpoint blockade therapy and the
progression of immunobiology in cancer have spurred an increasing interest in the …